ICON PLC

Icon plc (stylized as "ICON") is an Irish-headquartered multinational clinical research organisation (CRO). Icon conducts clinical trials on behalf of pharmaceutical and biotechnology companies and provides services related to drug development and guiding clinical trial progress. As of December 2025 Icon had approximately 40,100 employees in 55 countries.

Operations Icon provides outsourced drug development, clinical research, and consulting services for pharmaceutical, biotechnology, medical device, and government organizations. The company supports therapies throughout the development lifecycle, from early-stage research and clinical trial design through Phase I–IV clinical trials and commercialization. Its services include clinical trial management, laboratory and imaging services, patient recruitment, data analysis, and regulatory and market access consulting across a range of therapeutic areas.

History Icon was founded in Ireland, by John Climax and Ronan Lambe in 1990. Since January 2010, Climax has held a position on the board of directors. Lambe retired from the board of directors in 2018. Between 1991 and 1996, Icon opened offices in the United Kingdom, United States, Germany, and Japan. Two years later, Icon shares began trading on Nasdaq, providing the company with additional capital to support international expansion and acquisitions. In 2006, Icon acquired Ovation Research Group, expanding its capabilities in health outcomes research and health economics. In 2014, Icon expanded its capabilities in adaptive clinical trial design and execution with the acquisition of Aptiv Solutions. In 2021, Icon completed its US$12 billion acquisition of PRA Health Sciences. The transaction expanded the company's global clinical research operations and created one of the largest contract research organizations. On September 4, 2025, Icon announced that Steve Cutler would be stepping down from his position as CEO. Barry Balfe, the company's Chief Operating Officer, was promoted to Chief Executive Officer.

Acquisitions 2000: Icon acquired UK-based regulatory consultancy, YRCR Ltd.; Central Laboratory in New York; and bioanalytical consultancy, Pacific Research 2002: Icon acquired clinical research provider, BPA. 2003: Icon acquired Medieval, a UK-based Phase I facility, and US consulting firm, Globomax 2004: Icon acquired medical imaging specialist, Beacon Bioscience Inc. 2006: Icon acquired outcomes research and health economics specialist, Ovation Research Group 2007: Icon acquired European staffing group, DOCS International 2008: Icon acquired US phase I provider, Healthcare Discoveries and US bioanalytical lab, Prevalere Life Sciences 2009: Icon acquired Veeda Laboratories, a UK biomarker lab 2010: Icon acquired Timaq Medical Imaging Inc. 2011: Icon acquired Oxford Outcomes, an international health outcomes consultancy and Firecrest Clinical, a technology provider specialising in site performance and study management 2012: Icon acquired PriceSpective, a global value strategy consultancy and Chinese CRO, BeijingWits 2013: Icon acquired staffing and FSP providers, ClinForce and Assent and Akos, an EU provider of pharmacovigilance and drug safety services 2014: Icon acquired Aptiv Solutions, a market leader in adaptive trial design and execution 2015: Icon acquired MediMedia Pharma Solutions to enhance market access and scientific communications capabilities, and PMG Research Inc., an integrated network of clinical research sites in the US 2016: Icon acquired Clinical Research Management Inc., to extend its presence in the government-sponsored research market 2017: Icon acquired MAPI Group, thereby becoming the world's second-largest provider of late-phase services 2019: Icon acquired Symphony Clinical Research, a leading provider of at-home patient services and site-support services; MediNova, an integrated network of clinical research sites across EMEA; and MolecularMD, to enhance its laboratory offerings in molecular diagnostic testing and immunohistochemistry 2020: Icon acquired MedPass International, a leading European medical device CRO, regulatory and reimbursement consultancy 2021: Icon acquired PRA Health Sciences, a competitor offering clinical research services, for US$12 billion. Upon completion of the transaction, PRA shareholders will own approximately 34 percent of the shares of the combined company and Icon shareholders will own approximately 66 percent.

Finances

Recognition In 2018, Icon won PharmaTimes Clinical Researcher of the Year. In 2021, Icon was awarded PharmaTimes Clinical Research Company of the Year, and in 2022, won Best Contract Research Organisation (FSP) at the Scrip Awards.

Tags